{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+B&page=9", "query": { "intervention": "High Dose Drug B", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 266, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+B&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+B&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T22:55:39.194Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03263026", "title": "Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Enzastaurin Hydrochloride", "type": "DRUG" }, { "name": "R-CHOP + placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Denovo Biopharma LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2018-03-20", "completion_date": "2022-08-11", "has_results": true, "last_update_posted_date": "2025-01-23", "last_synced_at": "2026-11-10T22:55:39.194Z", "location_count": 27, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 22 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03263026" }, { "nct_id": "NCT07226362", "title": "A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Safety, and Tolerability" ], "interventions": [ { "name": "DHE inhalation powder low dose administered via dry powder inhaler (DPI) device", "type": "COMBINATION_PRODUCT" }, { "name": "DHE inhalation powder high dose administered via dry powder inhaler (DPI) device", "type": "COMBINATION_PRODUCT" }, { "name": "DHE injected intravenously (1 mg)", "type": "DRUG" }, { "name": "DHE 2 mg administered by nasal spray (Migranal®)", "type": "DRUG" }, { "name": "Metoclopramide 10mg", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Aspeya Switzerland SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2025-06-09", "completion_date": "2025-10-02", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-11-10T22:55:39.194Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226362" }, { "nct_id": "NCT06890884", "title": "A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Zilovertamab vedotin", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Rituximab Biosimilar", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 594, "start_date": "2025-04-11", "completion_date": "2032-12-16", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-10T22:55:39.194Z", "location_count": 74, "location_summary": "Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 65 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06890884" }, { "nct_id": "NCT00790595", "title": "Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "SU011248", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "18 Years to 75 Years · Male only" }, "enrollment_count": 6, "start_date": "2006-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-07-31", "last_synced_at": "2026-11-10T22:55:39.194Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00790595" }, { "nct_id": "NCT01072175", "title": "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK2118436", "type": "DRUG" }, { "name": "GSK1120212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2010-03-26", "completion_date": "2018-02-27", "has_results": true, "last_update_posted_date": "2019-07-05", "last_synced_at": "2026-11-10T22:55:39.194Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01072175" }, { "nct_id": "NCT01969123", "title": "Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease", "Dementia" ], "interventions": [ { "name": "Drug: EVP-6124", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "FORUM Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 474, "start_date": "2013-10", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2016-05-03", "last_synced_at": "2026-11-10T22:55:39.194Z", "location_count": 44, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01969123" }, { "nct_id": "NCT07664176", "title": "NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma", "High Grade Gliomas", "Medulloblastoma Recurrent", "Ependymoma Recurrent", "Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS", "Brain Tumor Recurrent" ], "interventions": [ { "name": "NeuroNavigation-Guided Focused Ultrasound (NgFUS)", "type": "DEVICE" }, { "name": "Lumason", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "3 Years to 25 Years" }, "enrollment_count": 30, "start_date": "2026-09", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-11-10T22:55:39.194Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07664176" }, { "nct_id": "NCT07215273", "title": "Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Mould Infection" ], "interventions": [ { "name": "EL219", "type": "DRUG" }, { "name": "Active Comparator- IV Antifungal (LAmB or voriconazole)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-02-13", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-10T22:55:39.194Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215273" }, { "nct_id": "NCT02278328", "title": "MEG Study of Acute STX209 Effects in ASD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Autism Disorder" ], "interventions": [ { "name": "STX209 (15mg)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "STX209 (30mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Timothy Roberts", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "17 Years", "sex": "MALE", "summary": "14 Years to 17 Years · Male only" }, "enrollment_count": 25, "start_date": "2016-02", "completion_date": "2019-09-27", "has_results": true, "last_update_posted_date": "2019-10-21", "last_synced_at": "2026-11-10T22:55:39.194Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02278328" }, { "nct_id": "NCT03385239", "title": "Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertriglyceridemia", "Cardiovascular Diseases" ], "interventions": [ { "name": "ISIS 678354", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akcea Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 114, "start_date": "2018-01-30", "completion_date": "2020-02-25", "has_results": true, "last_update_posted_date": "2023-01-11", "last_synced_at": "2026-11-10T22:55:39.194Z", "location_count": 24, "location_summary": "Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more", "locations": [ { "city": "Cottonwood", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Carmichael", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03385239" } ] }